NASDAQ:UBX

Unity Biotechnology Stock Forecast, Price & News

$3.87

-0.36 (-8.51 %)

(As of 10/30/2020 12:00 AM ET)

Add

Compare

Today's Range

$3.80

Now: $3.87▼

$4.25

50-Day Range

$2.94

MA: $3.71▼

$4.23

52-Week Range

$2.72

Now: $3.87▼

$15.44

Volume743,753 shs

Average Volume709,829 shs

Market Capitalization$201.39 million

P/E RatioN/A

Dividend YieldN/A

Beta-0.15

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 that is in Phase 1 clinical study for musculoskeletal disease; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was founded in 2009 and is headquartered in Brisbane, California.

Beat the Market (BTM) Rank^™

4.2 Analyst's Opinion

Consensus Rating
Unity Biotechnology has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, 4 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $7.00, Unity Biotechnology has a forecasted upside of 80.9% from its current price of $3.87.
Amount of Analyst Coverage
Unity Biotechnology has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.5 Community Rank

Outperform Votes
Unity Biotechnology has received 137 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Unity Biotechnology has received 133 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Unity Biotechnology has received 50.74% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Unity Biotechnology and other stocks. Vote “Outperform” if you believe UBX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe UBX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Unity Biotechnology does not currently pay a dividend.
Dividend Growth
Unity Biotechnology does not have a long track record of dividend growth.

2.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Unity Biotechnology insiders have not sold or bought any company stock.
Percentage Held by Insiders
37.30% of the stock of Unity Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
47.89% of the stock of Unity Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Unity Biotechnology are expected to grow in the coming year, from ($1.75) to ($1.60) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Unity Biotechnology is -2.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Unity Biotechnology is -2.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Overall Beat the Market Rank^™

1.86 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry N/A

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:UBX

Previous Symbol

CUSIPN/A

CIK1463361

WebN/A

PhoneN/A

Employees94

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Outstanding Shares52,040,000

Market Cap$201.39 million

Next Earnings Date11/4/2020 (Estimated)

OptionableNot Optionable

$3.87

-0.36 (-8.51 %)

(As of 10/30/2020 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive UBX News and Ratings via Email

Sign-up to receive the latest news and ratings for UBX and its competitors with MarketBeat's FREE daily newsletter.

Unity Biotechnology (NASDAQ:UBX) Frequently Asked Questions

How has Unity Biotechnology's stock price been impacted by Coronavirus?

Unity Biotechnology's stock was trading at $5.39 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, UBX stock has decreased by 28.2% and is now trading at $3.87.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Unity Biotechnology?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Unity Biotechnology in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Unity Biotechnology.

When is Unity Biotechnology's next earnings date?

Unity Biotechnology is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Unity Biotechnology.

How were Unity Biotechnology's earnings last quarter?

Unity Biotechnology Inc (NASDAQ:UBX) released its earnings results on Friday, July, 31st. The company reported ($0.38) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.51) by $0.13.
View Unity Biotechnology's earnings history.

What price target have analysts set for UBX?

6 equities research analysts have issued twelve-month price targets for Unity Biotechnology's shares. Their forecasts range from $4.00 to $20.00. On average, they anticipate Unity Biotechnology's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 80.9% from the stock's current price.
View analysts' price targets for Unity Biotechnology.

Who are some of Unity Biotechnology's key competitors?

Some companies that are related to Unity Biotechnology include Oxford BioMedica (OXBDF), Codexis (CDXS), iTeos Therapeutics (ITOS), Vectura Group (VEGPF), Tabula Rasa HealthCare (TRHC), Personalis (PSNL), AnaptysBio (ANAB), Sienna Senior Living Inc. (SIA.TO) (SIA), Alector (ALEC), I-Mab (ARQT), Precigen (PGEN), Pliant Therapeutics (PLRX), Vapotherm (VAPO), Passage Bio (PASG) and BellRing Brands (BRBR).
View all competitors.

What other stocks do shareholders of Unity Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Unity Biotechnology investors own include NIO (NIO), Inseego (INSG), NVIDIA (NVDA), Editas Medicine (EDIT), Advanced Micro Devices (AMD), Canopy Growth (CGC), VBI Vaccines (VBIV), Enphase Energy (ENPH), Sorrento Therapeutics (SRNE) and Opko Health (OPK).

Who are Unity Biotechnology's key executives?

Unity Biotechnology's management team includes the following people:

Dr. Nathaniel E. David, Co-Founder, Pres & Exec. Director (Age 52, Pay $640.86k)
Mr. Robert C. Goeltz II, Chief Financial Officer (Age 47, Pay $577.3k)
Dr. Anirvan Ghosh, Director & CEO (Age 56)
Dr. Jan M. van Deursen, Founder
Dr. Judith Campisi, Founder

When did Unity Biotechnology IPO?

(UBX) raised $85 million in an initial public offering (IPO) on Thursday, May 3rd 2018. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup acted as the underwriters for the IPO and Mizuho Securities was co-manager.

What is Unity Biotechnology's stock symbol?

Unity Biotechnology trades on the NASDAQ under the ticker symbol "UBX."

Who are Unity Biotechnology's major shareholders?

Unity Biotechnology's stock is owned by many different institutional and retail investors. Top institutional shareholders include Moloney Securities Asset Management LLC (0.09%), DekaBank Deutsche Girozentrale (0.02%) and BNP Paribas Arbitrage SA (0.02%).

Which major investors are buying Unity Biotechnology stock?

UBX stock was bought by a variety of institutional investors in the last quarter, including Moloney Securities Asset Management LLC, DekaBank Deutsche Girozentrale, and BNP Paribas Arbitrage SA.

How do I buy shares of Unity Biotechnology?

Shares of UBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Unity Biotechnology's stock price today?

One share of UBX stock can currently be purchased for approximately $3.87.

How big of a company is Unity Biotechnology?

Unity Biotechnology has a market capitalization of $201.39 million. Unity Biotechnology employs 94 workers across the globe.

This page was last updated on 10/31/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings